Tolvaptan
Jinarc® (Tolvaptan)
A Managed Access Protocol (MAP) is in place for tolvaptan (Jinarc®) for the treatment of autosomal dominant polycystic kidney disease (ADPKD). This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of tolvaptan under the High Tech Arrangement.
Applications for reimbursement approval for tolvaptan for the treatment of ADPKD under the High Tech Arrangement will only be considered from consultant nephrologists registered with the Irish Medical Council, who have agreed to the terms of this MAP and have been approved by the HSE. The approved consultant must submit an application for individual reimbursement approval for each patient.
A copy of the MAP for tolvaptan and the application form for individual reimbursement approval can be found in the Related Files section below.
For further information, please contact mmp@hse.ie.
More information is available on the Data Snapshots and Publications - HSE.ie